02622     2200421   4500001002100000005001500021035002000036007000300056008003900059020001500098084001500113100002500128245013900153250003900292260000900331300001200340650001500352650002900367650002300396650002800419650002300447700002000470700002100490700001800511700002600529700002200555700002000577700002900597700002200626700002500648700002100673700002400694700002100718700002100739700002000760520138900780856003102169INLIS00000000001875720240212081818  a0010-0224000007ta240212                |          | |    aARTVET2383  aARTVET23830 aBlacksell, Stuart D.1 aThe Biosafety Research Road Map :bThe Search for Evidence to Support Practices in the Laboratory—SARS-CoV-2 /cBlacksell, Stuart D.  aApplied Biosafety, Vol, 28, No, 2.  c2023  a87–95 4aSARS-CoV-2 4apathogen characteristics 4abiosafety evidence 4abiosafety knowledge gap 4abiorisk management0 aDhawan, Sandhya0 aKusumoto, Marina0 aLe, Kim Khanh0 aSummermatter, Kathrin0 aO’Keefe, Joseph0 aKozlova, Joseph0 aAlmuhairi, Salama Suhail0 aSendow, Indrawati0 aScheel, Christina M.0 aAhumibe, Anthony0 aMasuku, Zibusiso M.0 aKojima, Kazunobu0 aHarper, David R.0 aHamilton, Keith  aIntroduction: The SARS-CoV-2 virus emerged as a novel virus and is the causative agent of the COVID-19
pandemic. It spreads readily human-to-human through droplets and aerosols. The Biosafety Research
Roadmap aims to support the application of laboratory biological risk management by providing an evi-
dence base for biosafety measures. This involves assessing the current biorisk management evidence
base, identifying research and capability gaps, and providing recommendations on how an evidence-
based approach can support biosafety and biosecurity, including in low-resource settings.
Methods: A literature search was conducted to identify potential gaps in biosafety and focused on ?ve main
sections, including the route of inoculation/modes of transmission, infectious dose, laboratory-acquired
infections, containment releases, and disinfection and decontamination strategies.
Results: There are many knowledge gaps related to biosafety and biosecurity due to the SARS-CoV-2 virus’s
novelty, including infectious dose between variants, personal protective equipment for personnel handling
samples while performing rapid diagnostic tests, and laboratory-acquired infections. Detecting vulnerabil-
ities in the biorisk assessment for each agent is essential to contribute to the improvement and develop-
ment of laboratory biosafety in local and national systems.  aDOI: 10.1089/apb.2022.0039